See every side of every news story
Published loading...Updated

Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases – Optimum Strategic Communications

Summary by Optimum Strategic Communications
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation, tissue damage, and pain  Strasbourg, France – Montreal, Canada – Boston, United States, March 20, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Optimum Strategic Communications broke the news in on Thursday, March 20, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.